Inovio中国合作伙伴III期试验成功

环球市场播报

05/23

　　Inovio Pharmaceuticals股价走高，此前其中国合作伙伴ApolloBio在治疗宫颈不典型增生的治疗性DNA疫苗VGX-3100的III期关键性试验中取得成功。该试验达到了第36周复合缓解率的主要终点。Inovio于2018年将VGX-3100授权给ApolloBio，后者承担开发费用，Inovio有权获得最高2000万美元的监管里程碑付款及大中华区净销售额的双位数分层特许权使用费。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：张俊 SF065

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2637634193"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2637634193\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2637634193?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-05-23 03:31","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2637634193","market":"sg","top_or_hot":-1,"title":"Inovio中国合作伙伴III期试验成功","media":"环球市场播报","content":"<html><body><div>\n<p>　　Inovio Pharmaceuticals股价走高，此前其中国合作伙伴ApolloBio在治疗宫颈不典型增生的治疗性DNA疫苗VGX-3100的III期关键性试验中取得成功。该试验达到了第36周复合缓解率的主要终点。Inovio于2018年将VGX-3100授权给ApolloBio，后者承担开发费用，Inovio有权获得最高2000万美元的监管里程碑付款及<a href=\"https://laohu8.com/S/00021\">大中华</a>区净销售额的双位数分层特许权使用费。</p>\n<div>\n<div><img src=\"\"/></div>\n<div>海量资讯、精准解读，尽在新浪财经APP</div>\n</div>\n<p>责任编辑：张俊 SF065</p>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inovio中国合作伙伴III期试验成功</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInovio中国合作伙伴III期试验成功\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-23 03:31 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2026-05-23/doc-inhyvhua5796224.shtml><strong>环球市场播报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Inovio Pharmaceuticals股价走高，此前其中国合作伙伴ApolloBio在治疗宫颈不典型增生的治疗性DNA疫苗VGX-3100的III期关键性试验中取得成功。该试验达到了第36周复合缓解率的主要终点。Inovio于2018年将VGX-3100授权给ApolloBio，后者承担开发费用，Inovio有权获得最高2000万美元的监管里程碑付款及大中华区净销售额的双位数分层特许权使用费...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-05-23/doc-inhyvhua5796224.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"III","symbol_name":"信息服务","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-23/doc-inhyvhua5796224.shtml","article_id":"2637634193","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2637634193","pubTimestamp":1779478260,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"Inovio Pharmaceuticals股价走高，此前其中国合作伙伴ApolloBio在治疗宫颈不典型增生的治疗性DNA疫苗VGX-3100的III期关键性试验中取得成功。该试验达到了第36周复合缓解率的主要终点。Inovio于2018年将VGX-3100授权给ApolloBio，后者承担开发费用，Inovio有权获得最高2000万美元的监管里程碑付款及大中华区净销售额的双位数分层特许权使用费。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"III":"信息服务","BK4134":"信息科技咨询与其它服务"},"translate_title":"Inovio China Partner Phase III Trial Successful","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1.5},"content_text":"Inovio Pharmaceuticals股价走高，此前其中国合作伙伴ApolloBio在治疗宫颈不典型增生的治疗性DNA疫苗VGX-3100的III期关键性试验中取得成功。该试验达到了第36周复合缓解率的主要终点。Inovio于2018年将VGX-3100授权给ApolloBio，后者承担开发费用，Inovio有权获得最高2000万美元的监管里程碑付款及大中华区净销售额的双位数分层特许权使用费。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}